|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Neurological Disorders and Stroke (NINDS) |
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001208 |
Purpose
Botulism is a severe form of food poisoning caused by bacteria. This bacteria produces several toxins one of which is botulinum toxin A. This toxin causes the symptoms of food poisoning. Small amounts of botulinum toxin A have been used to treat speech disorders such as stuttering and problems with the muscles of the eyes.
The study examines the effectiveness of botulinum toxin as treatment for a variety of movement disorders. The goals of the study are to refine the technique of treatment to provide the best results, to improve the understanding of how botulinum toxin works on movement disorders, and find other conditions that may be treatable with botulinum toxin.
In addition, researchers also plan to study the possible use of botulinum toxin F alone and in combination with botulinum toxin A in patients who do not respond to botulinum A toxin treatment. ...
| Condition |
|
Chorea Drug Induced Dyskinesia Movement Disorder Muscular Disease Tic Disorder |
| Genetics Home Reference related topics: | chorea-acanthocytosis early-onset primary dystonia essential tremor familial paroxysmal nonkinesigenic dyskinesia McLeod neuroacanthocytosis syndrome |
| MedlinePlus related topics: | Movement Disorders Muscle Disorders Neurologic Diseases Poisoning Stuttering |
| ChemIDplus related topics: | Clostridium botulinum toxin |
| Study Type: | Observational |
| Official Title: | A Training Protocol for the Use of Botulinum Toxin in the Treatment of Neurological Disorders |
| Estimated Enrollment: | 1000 |
| Study Start Date: | November 1985 |
The efficacy of botulinum toxin (btx) has now been demonstrated for a variety of diseases associated with involuntary muscle spasms or movement. The application of botulinum toxin therapy to movement disorders requires treatment tailored to the individual patient and specific techniques of injection. This protocol 1) provides for training of physicians in the use of botulinum toxin and 2) allows us to provide botulinum toxin injections for patients participating in other studies on the physiology of sensorimotor systems and physiological effects of botulinum toxin.
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients will be eligible for participation if they have a disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia.
EXCLUSION CRITERIA:
Patients will be excluded form participation if
Contacts and Locations| Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
| Contact: TTY | 1-866-411-1010 |
| United States, Maryland | |||||
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting | ||||
| Bethesda, Maryland, United States, 20892 | |||||
More Information
NIH Clinical Center Detailed Web Page 
  |
| Study ID Numbers: | 850195, 85-N-0195 |
| First Received: | November 3, 1999 |
| Last Updated: | July 18, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001208 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
|